Open Label, Dose Finding Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Atezolizumab (Primary) ; RG 6146 (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Roche
- 14 Dec 2017 Planned End Date changed from 19 Sep 2019 to 23 Sep 2020.
- 14 Dec 2017 Planned primary completion date changed from 19 Sep 2019 to 23 Sep 2020.
- 02 Nov 2017 Status changed from not yet recruiting to recruiting.